Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

Journal of Clinical Investigation

Volumn 121, Issue 6, 2011, Pages 2350-2360

  Baitsch, Lukas ^a   Baumgaertner, Petra ^a   Devêvre, Estelle ^a   Raghav, Sunil K ^b   Legat, Amandine ^a   Barba, Leticia ^a   Wieckowski, Sébastien ^c   Bouzourene, Hanifa ^c   Deplancke, Bart ^b   Romero, Pedro ^a   Rufer, Nathalie ^a,c   Speiser, Daniel E ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b EPFL   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; MELAN A;

ARTICLE; BLOOD; CANCER IMMUNIZATION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL SPECIFICITY; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; EFFECTOR CELL; EPSTEIN BARR VIRUS; EXHAUSTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LOW DRUG DOSE; MELANOMA; METASTASIS; MOLECULAR GENETICS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION PROFILING; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MART-1 ANTIGEN; MELANOMA; MOLECULAR SEQUENCE DATA; RECEPTORS, IMMUNOLOGIC; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; VACCINATION; VIRUS LATENCY;

EID: 79957925314     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI46102     Document Type: Article

References (49)

1. Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr Opin Immunol. 2010;22(2):223-230.
2. Wherry EJ, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670-684. (Pubitemid 47615511)
3. Turner SJ, Kedzierska K, La Gruta NL, Webby R, Doherty PC. Characterization of CD8+ T cell repertoire diversity and persistence in the influenza A virus model of localized, transient infection. Semin Immunol. 2004;16(3):179-184. (Pubitemid 38569898)
4. Gallimore A, Hengartner H, Zinkernagel R. Hierarchies of antigen-specific cytotoxic T cell responses. Immunol Rev. 1998;164:29-36. (Pubitemid 28438393)
5. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999; 17:51-88. (Pubitemid 29241119)
6. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008; 14(6):623-628. (Pubitemid 351809548)
7. Appay V, Rowland-Jones SL. Lessons from the study of T cell differentiation in persistent human virus infection. Semin Immunol. 2004;16(3):205-212. (Pubitemid 38569901)
8. + T cells. PLoS Pathog. 2010;6(3):e1000798.
9. + T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis. 2004;189(9):1619-1627.
10. Guerreiro M, et al. Human peripheral blood and bone marrow Epstein-Barr virus-specific T cell repertoire in latent infection reveals distinct memory T cell subsets. Eur J Immunol. 2010;40(6):1566-1576.
11. Zajac AJ, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188(12):2205-2213. (Pubitemid 29028493)
12. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 1993;362(6422):758-761. (Pubitemid 23125981)
13. + T cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol. 2003;77(8):4911-4927.
14. Yi JS, Cox MA, Zajac AJ. T cell exhaustion: characteristics, causes and conversion. Immunology. 2010; 129(4):474-481.
15. + T cells during chronic viral infection. Nature. 2006;439(7077):682-687.
16. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215-229. (Pubitemid 40364823)
17. Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med. 2003;9(7):861-866. (Pubitemid 36889927)
18. Quigley M, et al. Transcriptional analysis of HIVspecific CD8(+) T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med. 2010; 16(10):1147-1151.
19. Speiser DE, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005;115(3):739-746. (Pubitemid 40322250)
20. + T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004; 64(8):2865-2873.
21. + T cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010;33(8):848-858.
22. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233-240.
23. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207(10):2187-2194.
24. + T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537-1544.
25. Appay V, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol. 2006; 177(3):1670-1678. (Pubitemid 44092503)
26. Choi S, Schwartz RH. Molecular mechanisms for adaptive tolerance and other T cell anergy models. Semin Immunol. 2007;19(3):140-152. (Pubitemid 46824071)
27. Derre L, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest. 2010; 120(1):157-167.
28. Appay V, et al. Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. J Immunol. 2007;179(11):7406-7414.
29. Critchley-Thorne RJ, Yan N, Nacu S, Weber J, Holmes SP, Lee PP. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med. 2007;4(5):e176.
30. Cham CM, Xu H, O'Keefe JP, Rivas FV, Zagouras P, Gajewski TF. Gene array and protein expression profiles suggest post-transcriptional regulation during CD8+ T cell differentiation. J Biol Chem. 2003; 278(19):17044-17052. (Pubitemid 36799580)
31. Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF. Molecular signatures distinguish human central memory from effector memory CD8+ T cell subsets. J Immunol. 2005;175(9):5895-5903. (Pubitemid 41508074)
32. Bengsch B, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 2010;6(6):e1000947.
33. Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009; 10(1):29-37.
34. + T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2010;107(33):14733-14738.
35. Rey J, et al. The co-expression of 2B4 (CD244) and CD160 delineates a subpopulation of human CD8+ T cells with a potent CD160-mediated cytolytic effector function. Eur J Immunol. 2006;36(9):2359-2366. (Pubitemid 44420592)
36. Fourcade J, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175-2186.
37. McMahan RH, et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte- directed in vitro cytotoxicity. J Clin Invest. 2010;120(12):4546-4557.
38. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell. 2002;109(6):719-731. (Pubitemid 34722268)
39. Parish IA, et al. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood. 2009;113(19):4575-4585.
40. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T cell tolerance. Nature. 2005;437(7055):141-146. (Pubitemid 41613441)
41. Willimsky G, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med. 2008; 205(7):1687-1700. (Pubitemid 351962031)
42. Miller JD, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity. 2008;28(5):710-722.
43. Gaucher D, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med. 2008;205(13):3119-3131.
44. Barbey C, et al. IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J Immunol. 2007;178(6):3566-3574. (Pubitemid 46417623)
45. Lienard D, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004;4:4.
46. Romero P, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen- experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998;188(9):1641-1650. (Pubitemid 28516109)
47. Hadrup SR, et al. Parallel detection of antigen-specific T cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009;6(7):520-526.
48. Roederer M, Nozzi JL, Nason MC. SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A. 2011;79(2):167-174.
49. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550. (Pubitemid 41528093)